Skip to main content
NCBI home page
Gut logoLink to Gut
. 1985 May;26(5):438–444. doi: 10.1136/gut.26.5.438

Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

S M Wood, M E Kraenzlin, T E Adrian, S R Bloom
PMCID: PMC1432669  PMID: 2860052

Abstract

Seven patients with gut and pancreatic endocrine tumours have been treated with a long acting somatostatin analogue (SMS 201-995), given as a twice daily subcutaneous injection. This produced dramatic improvement in their endocrine related symptoms, in association with a fall in circulating tumour peptides. One of these patients has now been treated for seven months with this analogue which has controlled his previously life threatening diarrhoea caused by a malignant VIP secreting tumour. He gives his own injections twice daily, and has returned to a full and active life. This is a promising agent both for acute treatment of peptide hypersecretion, and for the long term management of some patients who are unresponsive to other available therapy.

Full text

PDF
438

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T. J., Pless SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982 Sep 13;31(11):1133–1140. doi: 10.1016/0024-3205(82)90087-x. [DOI] [PubMed] [Google Scholar]
  2. Bonfils S., René E., Pignal F., Rambaud J. C. Rebound effect after somatostatin treatment in Verner-Morrison syndrome. Lancet. 1979 Sep 1;2(8140):476–476. doi: 10.1016/s0140-6736(79)91533-2. [DOI] [PubMed] [Google Scholar]
  3. Fox P. S., Hofmann J. W., Decosse J. J., Wilson S. D. The influence of total gastrectomy on survival in malignant Zollinger-Ellison tumors. Ann Surg. 1974 Oct;180(4):558–566. doi: 10.1097/00000658-197410000-00020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Friesen S. R. Tumors of the endocrine pancreas. N Engl J Med. 1982 Mar 11;306(10):580–590. doi: 10.1056/NEJM198203113061005. [DOI] [PubMed] [Google Scholar]
  5. Gerich J. E., Patton G. S. Somatostatin. Physiology and clinical applications. Med Clin North Am. 1978 Mar;62(2):375–392. doi: 10.1016/s0025-7125(16)31813-2. [DOI] [PubMed] [Google Scholar]
  6. Johansson C., Wisén O., Efendić S., Uvnäs-Wallensten K. Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion. 1981;22(3):126–137. doi: 10.1159/000198619. [DOI] [PubMed] [Google Scholar]
  7. Krejs G. J., Browne R., Raskin P. Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes. Gastroenterology. 1980 Jan;78(1):26–31. [PubMed] [Google Scholar]
  8. Lehy T., Dubrasquet M., Brazeau P., Bonfils S. Inhibitory effect of prolonged administration of long-acting somatostatin on gastrin-stimulated fundic epithelial cell growth in the rat. Digestion. 1982;24(4):246–255. doi: 10.1159/000198804. [DOI] [PubMed] [Google Scholar]
  9. Long R. G., Barnes A. J., Adrian T. E., Mallinson C. N., Brown M. R., Vale W., Rivier J. E., Christofides N. D., Bloom S. R. Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue. Lancet. 1979 Oct 13;2(8146):764–767. doi: 10.1016/s0140-6736(79)92115-9. [DOI] [PubMed] [Google Scholar]
  10. Long R. G., Bryant M. G., Yuille P. M., Polak J. M., Bloom S. R. Mixed pancreatic apudoma with symptoms of excess vasoactive intestinal polypeptide and insulin: improvement of diarrhoea with metoclopramide. Gut. 1981 Jun;22(6):505–511. doi: 10.1136/gut.22.6.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Moertel C. G., Hanley J. A., Johnson L. A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980 Nov 20;303(21):1189–1194. doi: 10.1056/NEJM198011203032101. [DOI] [PubMed] [Google Scholar]
  12. Morisset J., Génik P., Lord A., Solomon T. E. Effects of chronic administration of somatostatin on rat exocrine pancreas. Regul Pept. 1982 Jun;4(1):49–58. doi: 10.1016/0167-0115(82)90108-2. [DOI] [PubMed] [Google Scholar]
  13. ROBERTSON J. I., PEART W. S., ANDREWS T. M. The mechanism of facial flushes in the carcinoid syndrome. Q J Med. 1962 Jan;31:103–123. [PubMed] [Google Scholar]
  14. Ruskoné A., René E., Chayvialle J. A., Bonin N., Pignal F., Kremer M., Bonfils S., Rambaud J. C. Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci. 1982 May;27(5):459–466. doi: 10.1007/BF01295657. [DOI] [PubMed] [Google Scholar]
  15. Sheppard M., Shapiro B., Pimstone B., Kronheim S., Berelowitz M., Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab. 1979 Jan;48(1):50–53. doi: 10.1210/jcem-48-1-50. [DOI] [PubMed] [Google Scholar]
  16. Voyles N. R., Bhathena S. J., Recant L., Meyers C. A., Coy D. H. Selective inhibition of glucagon and insulin secretion by somatostatin analogs. Proc Soc Exp Biol Med. 1979 Jan;160(1):76–79. doi: 10.3181/00379727-160-40393. [DOI] [PubMed] [Google Scholar]
  17. Wood S. M., Polak J. M., Bloom S. R. Gut hormone secreting tumours. Scand J Gastroenterol Suppl. 1983;82:165–179. [PubMed] [Google Scholar]
  18. Zollinger R. M., Martin E. W., Jr, Carey L. C., Sparks J., Minton J. P. Observations on the postoperative tumor growth behavior of certain islet cell tumors. Ann Surg. 1976 Oct;184(4):525–530. doi: 10.1097/00000658-197610000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES